Pooled CRISPR screens for drug target discovery

CRISPR screening has revolutionized the unbiased annotation of gene function, but most screens done so far have been confined to rather simplistic read-outs (usually life/death of the target cells). Combining CRISPR perturbation with single-cell sequencing allows researchers to assess much more complex phenotypes, thus effectively broadening the scope of these screens.

At Myllia, we use the CROP-Seq technology to perturb cells with CRISPR and profile transcriptional outcomes by RNA sequencing at single-cell resolution. Importantly, our technology is applicable across a wide range of cell types including primary immune cells.

Submit your credentials and explore our technology platform including many functional read-outs!